Last update 17 Apr 2024

Gemigliptin/Dapagliflozin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
gemigliptin/Dapagliflozin, Zemidapa
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
KR (04 Apr 2023),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC21H25ClO6
InChIKeyJVHXJTBJCFBINQ-ADAARDCZSA-N
CAS Registry461432-26-8

R&D Status

IndicationHighest PhaseCountry/LocationOrganization
Diabetes Mellitus, Type 2ApprovedKR
More
Login to view more data

Clinical Trial Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial Analysis

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free